Lung Cancer Test Kit
| Sample Type | Serum, Plasma |
| Pathology | For Lung Cancer |
| Tested Parameter | For Tumor Markers |
| Format | Cassette |
| Application Domain | Oncology |
This Progastrin-Releasing Peptide (pro-GRP) POCT Kit is designed to quantitatively detect Progastrin-Releasing Peptide in human serum and plasma samples using the self-developed LYOFIA® system.input:
output:It is intended solely for in vitro diagnostic purposes.input:
output:Summaryinput:
output:The most prevalent primary malignant tumor of the lung is lung cancer. It is also referred to as bronchial lung cancer, as the bronchial mucosal epithelium is the site of origin for the vast majority of lung cancers. The spread of lung cancer can extend to the surrounding region and even the entire body.input:
output:The morbidity and mortality rates of lung cancer have increased rapidly in countries worldwide, particularly in industrialized nations, over the past 50 years. Currently, lung cancer is the most prevalent form of cancer worldwide and the leading cause of cancer-related deaths. An estimated 600,000 individuals worldwide succumbed to lung cancer in 1995, and the incidence continues to rise annually. The prevalence of lung cancer among women is particularly elevated. It is the most prevalent cancer among men and the second most prevalent cancer among women, following breast cancer. In 2020, there were over 2.2 million new cases of lung cancer.input:
output:Why conduct a pro-GRP test?product-260-370input:
output:Although there are numerous cancers that affect the lungs, the term “lung cancer” is typically used to refer to two primary types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).input:
output:1. Pro-GRP has been widely recognized as a reliable, specific, and sensitive tumor marker for patients with small cell lung cancer (SCLC), both in limited (LD) and diffuse disease (DD). It is also a valuable tool for distinguishing SCLC from NSCLC. input:
output:2. Nisman et al. demonstrated that ProGRP had superior discriminating power in the detection of SCLC compared to other tumor markers.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
